Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer.
Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer.
复制标题
DOI：
10.1186/bcr3181
复制
发表时间：
2012-05-04
期刊：
影响因子：
--
通讯作者：
Buchholz TA
中科院分区：
文献类型：
--
作者：
McGovern SL;Qi Y;Pusztai L;Symmans WF;Buchholz TA
着丝粒蛋白A （CENP-A）是一种重要的着丝粒蛋白，与高级别癌症有关。本研究旨在确定CENP-A是否为未接受全身治疗的乳腺癌患者的预后因素，或对他莫昔芬或新辅助化疗反应的预测因素。研究人员测量了484例未接受全身治疗、276例接受他莫昔芬治疗和233例接受新辅助化疗的乳腺癌标本中CENP-A和CENP-B（一种独立于CENP-A结合的着丝粒蛋白）mRNA水平。确定了CENP-A、CENP-B、Ki-67、复发和化疗反应之间的关系。雌激素受体（ER）阴性肿瘤中CENP-A表达高于ER阳性肿瘤，且与Ki-67表达呈正相关。在未接受全身治疗或他莫昔芬的er阳性疾病患者中，较高水平的CENP-A与较低的5年远端无复发生存率（DRFS）相关。在包括Ki-67在内的多变量分析中，未接受全身治疗的er阳性疾病患者的复发风险比为10.9 (95% CI， 2.86至41.78,P = 0.00047)，而接受他莫昔芬治疗的er阳性疾病患者的复发风险比为1.64 （95% CI， 0.99至2.71,P = 0.054）。在er阴性肿瘤中，CENP-A不是一个独立的预后指标。对于er阳性和er阴性肿瘤，CENP-A都不是化疗反应的重要独立预测因子。对于未接受全身治疗的er阳性乳腺癌患者，CENP-A是一个重要的独立预后标志物，但对于接受他莫昔芬治疗的患者，其预测价值有限，并且不能预测对新辅助化疗的反应。
Centromere protein A (CENP-A), an essential centromere protein, has been associated with high grade cancers. This study was undertaken to determine if CENP-A is a prognostic factor for breast cancer patients not receiving systemic therapy or predictive of response to tamoxifen or neoadjuvant chemotherapy. mRNA levels of CENP-A and CENP-B, a centromere protein that binds independently of CENP-A, were measured in breast cancer specimens from 484 patients receiving no systemic therapy, 276 patients receiving tamoxifen, and 233 patients treated with neoadjuvant chemotherapy. Associations between CENP-A, CENP-B, Ki-67, relapse, and chemotherapy response were determined. CENP-A but not CENP-B was higher in estrogen receptor (ER)-negative tumors than ER-positive tumors and positively correlated with Ki-67 expression. Among patients with ER-positive disease who received no systemic therapy or tamoxifen, higher levels of CENP-A were associated with lower rates of 5-year distant relapse free survival (DRFS). On multivariate analyses including Ki-67, high CENP-A expression had a hazard ratio of 10.9 for relapse in patients with ER-positive disease not receiving systemic therapy (95% CI, 2.86 to 41.78; P = 0.00047) and 1.64 for patients with ER-positive disease receiving tamoxifen (95% CI, 0.99 to 2.71; P = 0.054). CENP-A was not an independent prognostic marker in ER-negative tumors. For both ER-positive and ER-negative tumors, CENP-A was not a significant independent predictor of chemotherapy response. CENP-A was a significant independent prognostic marker for patients with ER-positive breast cancer not treated with systemic therapy but had limited predictive value in tamoxifen treated patients and was not predictive of response to neoadjuvant chemotherapy.
登录
查看更多内容
影响因子：
11.2
作者：
Birkbak NJ;Eklund AC;Li Q;McClelland SE;Endesfelder D;Tan P;Tan IB;Richardson AL;Szallasi Z;Swanton C
通讯作者：
Swanton C
影响因子：
5.8
作者：
Hubbell, E;Liu, WM;Mei, R
通讯作者：
Mei, R
DOI：
10.1186/bcr2772
发表时间：
2010
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Li J;Humphreys K;Darabi H;Rosin G;Hannelius U;Heikkinen T;Aittomäki K;Blomqvist C;Pharoah PD;Dunning AM;Ahmed S;Hooning MJ;Hollestelle A;Oldenburg RA;Alfredsson L;Palotie A;Peltonen-Palotie L;Irwanto A;Low HQ;Teoh GH;Thalamuthu A;Kere J;D'Amato M;Easton DF;Nevanlinna H;Liu J;Czene K;Hall P
通讯作者：
Hall P
影响因子：
8
作者：
Millour, J.;Constantinidou, D.;Stavropoulou, A. V.;Wilson, M. S. C.;Myatt, S. S.;Kwok, J. M-M;Sivanandan, K.;Coombes, R. C.;Medema, R. H.;Hartman, J.;Lykkesfeldt, A. E.;Lam, E. W-F
通讯作者：
Lam, E. W-F
影响因子：
3.7
作者：
Li Y;Zhu Z;Zhang S;Yu D;Yu H;Liu L;Cao X;Wang L;Gao H;Zhu M
通讯作者：
Zhu M